CrushSCI.com
90.7Average days
79.5Median days
26Fastest days
193Longest days
5032025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

59 days

Shugan Xiaozhi formula reduces hepatic steatosis and stiffness in MASLD patients with elevated ALT: An exploratory 24-week randomized trial

Authors
Yuxin Sun; Zhiyi Han; Can Li; Die Hu; Fanci Xie; Qingqing Li; Hong Luo; Mianmian Liao; Xiaoling Zhou; Jingbao Hu; Shizao Mo; Nailiang Cai; Xiaojun Ma; Yu Lai; Shijun Zhang; Dan Li; Yufeng Xing; Hua Zhou; Guangdong TongShow moreShow less
Affiliations
Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China; The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China; Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, Guangxi, PR China; Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, PR China; Department of General Medicine, Longhua District People’s Hospital, Shenzhen, PR China; Dongguan Key Laboratory of Traditional Chinese Medicine Hepatology, the Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, PR China; The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China; Tengxian Hospital of Traditional Chinese Medicine, Guangxi Zhuang Autonomous Region, PR China; Sanya People’s Hospital, Jiefang Road, Tianya District, Sanya, Hainan, PR China; Foshan Hospital of Traditional Chinese Medicine, No. 6 Qinren Road, Foshan, PR China; Meizhou Hospital of Traditional Chinese Medicine, Meizhou, Guangdong, PR China; The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Er Road, Guangzhou, PR China; China Resources Sanjiu Modern Chinese Medicine Pharmaceutical Co., Ltd., PR China; Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), State Key Laboratory of Traditional Chinese Medicine Syndrome, State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangdong, PR ChinaShow moreShow less
Source PDF DOI Publisher page
169 days

Laminarin suppresses PD-L1 translation by targeting YTHDF1 to exert antitumor immunity in triple-negative breast cancer

Authors
Fangning Lou; Xiaoya Zhang; Jianuo Fu; Mengyao Liu; Yuan Zhu; Kaixian Chen; Mingyue Zheng; Sulin ZhangShow moreShow less
Affiliations
School of Pharmacy, China Pharmaceutical University, 639 Longmian Road, Nanjing, 211198, China; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou, 330106, China; University of Chinese Academy of Sciences, Beijing, 100049, China; Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China; School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, 110016, ChinaShow moreShow less
Source PDF DOI Publisher page
38 days

MT-Exo-derived miR-4651 and miR-6126 coordinately regulate the SRSF1–progerin and SP1–PrPᶜ axes to attenuate vascular aging in HGPS

Authors
Eun Young Joo; Unyoung Yoon; Jaeyoung Lee; Kyung Hee Jeong; Myung Shin Jeon; Ji Sun Park; Su-Jin Kim; Yun Seob Song; Ji Eun Lee; Gwang-Seong Choi; Sang Hun LeeShow moreShow less
Affiliations
Department of Biomedical Sciences, College of Medicine, BK21 FOUR Program in Biomedical Science & Engineering, Inha University, Incheon, Republic of Korea; Department of Pediatrics, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea; Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University, College of Medicine, Seoul, Republic of Korea; Department of Dermatology, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of KoreaShow moreShow less
Source PDF DOI Publisher page
26 days

A RISKmilk framework for predicting drug and chemical exposure in human milk during breastfeeding

Authors
Xinyang Liu; Wei Wang; Ping Xiong; Nannan Wang; Jinying Zhu; Yinyun Qin; Dunjin Chen; Jingsi Chen; Defang OuyangShow moreShow less
Affiliations
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macao Special Administrative Region of China; Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California San Francisco, 600 16th St, San Francisco, CA, 94158, United States; Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China; Guangdong-Hong Kong-Macao Great Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China; Department of Biological Sciences, Faculty of Science, University of Macau, Macao Special Administrative Region of ChinaShow moreShow less
Source PDF DOI Publisher page
78 days

IDO1 integrates gut microbiota-derived SCFAs signals and host WNT/TGF-β pathways to mediate the anti-colorectal cancer effects of licorice flavonoids

Authors
Yamei Li; Junya Wen; Dehao Huang; Zhuxian Wang; Yiquan Peng; Yuxuan Xu; Janar Jenis; Shijia Sun; Ming Luo; Lijuan Zeng; Lehuan Ni; Zhenyu Hao; Tairun Huang; Cuiping Jiang; Chunyan Shen; Li Liu; Hongxia Zhu; Qing Li; Qiang LiuShow moreShow less
Affiliations
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China; Director of Research Center for Medicinal Plants, Al-Farabi Kazakh National University, Almaty, Kazakhstan; Macau University of Science and Technology, Macau, China; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China; Dermatology Hospital, Southern Medical University, Guangzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
193 days

NMN mitigates LPS-induced liver injury by inhibiting ferroptosis via suppression of the cGAS-STING-ACSL4 axis

Authors
Yan Liao; Cheng-long Zhu; Wang-zhe-qi Zhang; Lin-dong Cheng; Yang Liu; Yi Wang; Tian Zhou; Jia-xin Zhao; Jin-jun Bian; Zui Zou; Miao ZhouShow moreShow less
Affiliations
Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China; School of Anesthesiology, Naval Medical University, Shanghai, 200433, China; Graduate School, Hebei North University, Hebei, 075000, China; Department of Anesthesiology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University, Nanjing, Jiangsu, 210009, ChinaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does PHARMACOLOGICAL RESEARCH take to review a manuscript?

As of 2026-11-19, CrushSCI has 16 complete review records for PHARMACOLOGICAL RESEARCH. The fastest paper went from submission to acceptance in 26 days (A RISKmilk framework for predicting drug and chemical exposure in human milk during breastfeeding, received 2026-08-27, accepted 2026-09-22); the slowest took 193 days. The average is 90.7 days and the median is 79.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.